Raymond James Financial Services Advisors’s Moleculin Biotech MBRX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-32	Closed	-$44K	–	2870
2020 Q1	$44K	Buy	32 +23	+256%	+$39.2K	﹤0.01%	2325
2019 Q4	$18K	Hold	9	–	–	﹤0.01%	2807
2019 Q3	$22K	Hold	9	–	–	﹤0.01%	2745
2019 Q2	$24K	Buy	9 +3	+50%	+$8.15K	﹤0.01%	2779
2019 Q1	$11K	Hold	6	–	–	﹤0.01%	2769
2018 Q4	$13K	Hold	6	–	–	﹤0.01%	2532
2018 Q3	$20K	Hold	6	–	–	﹤0.01%	2764
2018 Q2	$23K	Hold	6	–	–	﹤0.01%	2719
2018 Q1	$23K	Buy	+6	New	+$26K	﹤0.01%	2490

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

WIC

Whitegate Investment Counselors Concord, New Hampshire $315M AUM 10.6% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raymond James Financial Services Advisors's MBRX Position: Q2 2020 in Review

Raymond James Financial Services Advisors sold out of Moleculin Biotech (MBRX) in Q2 2020, closing a stake of 32 shares — an estimated $44K sold.

Raymond James Financial Services Advisors first reported a position in MBRX in Q1 2018 and held it in 9 quarters. The position peaked at $44K in Q1 2020. 24 funds tracked by Wall St. Rank hold MBRX as of Q2 2020.

Raymond James Financial Services Advisors reported no remaining Moleculin Biotech position as of Q2 2020 after selling out during the quarter.
Raymond James Financial Services Advisors sold 32 Moleculin Biotech shares in Q2 2020, an estimated $44K.
Raymond James Financial Services Advisors first reported a position in Moleculin Biotech in Q1 2018 and held it in 9 quarters.
Raymond James Financial Services Advisors's Moleculin Biotech position peaked at $44K in Q1 2020.
24 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2020.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2020, filed 17 Jul 2020.